Cas 136790-76-6 Lubiprostone RU 0211 For Soften Stool Increase Motility

Lubiprostone, also known as RU-0211, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006. Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).

Related Prodcuts:

(+)-Cloprostenol; Cloprostenol; Misoprostol; Carboprost; Travoprost; Tafluprost; Dinoprostone; Dinoprost; Trometamol; Alprostadil; Iloprost; Limaprost; Bimatoprost; Latanoprost; Lubiprostone hemiketal; Lubiprostone Intermediate

[1] Bijvelds MJ, et al. Gastroenterology, 2009, 137(3), 976-985.

[2] Bassil AK, et al. Br J Pharmacol, 2008, 154(1), 126-135.

[3] Moeser AJ, et al. Am J Physiol Gastrointest Liver Physiol, 2007, 292(2), G647-656.